Nautilus Announces 2026 Revenue Forecast Increase and Proteoform Assay Roadmap
Precommercial biotechnology firm Nautilus (NAUT) has raised its full-year 2026 revenue forecast, stating it will exceed the previous $500,000 estimate. The company is pivoting resources toward measuring proteoforms—structural variants of protein molecules—with a strategic goal to develop 20 commercial standardized testing assays by mid-2028. Technical milestones include successful precision testing on oncology targets AKT1, EGFR, and P53, which matched the performance of the company's mature tau assay in significantly less time than previous developments. Financially, Nautilus maintains a strong liquidity position with $114.3 million in cash reserves, providing an operational runway into the first quarter of 2028 as it prepares for the mid-2027 launch of its Voyager platform.
Tickers: $NAUT
Topics: biotechnology earnings report proteoform assays revenue guidance